Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $37.33 USD
Change Today +0.59 / 1.61%
Volume 350.5K
CEMP On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Key Developments

Cempra, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:00 AM

Cempra, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Prabhavathi B. Fernandes, Founder, Chief Executive Officer, President and Director.

Cempra, Inc. Presents Results from Its Phase 3 Clinical Trial

Cempra, Inc. is presenting results from its Phase 3 clinical trial demonstrating the statistical non-inferiority of oral solithromycin versus oral moxifloxacin for the treatment of community acquired bacterial pneumonia (CABP). Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP and the solithromycin early clinical response (ECR) and short term follow-up (SFU) rates were numerically higher than moxifloxacin in the elderly, the patients at greater risk for CABP. Solithromycin was non-inferior to moxifloxacin on every pre-specified outcome measure in the study. The study consisted of a 1:1 randomization of 860 CABP patients to oral solithromycin for 5 days or oral moxifloxacin for 7 days, stratified by geographic region, by history of asthma and/or chronic obstructive pulmonary disease (COPD), and by PORT score (II vs. III/IV). PORT II severity pneumonia was capped in the study at 50%. The primary endpoint (for FDA) was non-inferiority (NI) in ECR rate at 72 hours in the intent-to-treat (ITT) population. The primary endpoint (for EMA) was NI in success rate at SFU visit, 5 to 10 days after end of therapy in the ITT and clinically-evaluable (CE) populations. Patients randomized to solithromycin received an 800 mg loading dose on day 1, 400 mg on days 2-5 and placebo on days 6 and 7. Patients in the moxifloxacin treatment arm received 400 mg on days 1-7. Oral solithromycin demonstrated statistical non-inferiority to oral moxifloxacin for the treatment of CABP with a treatment success rate in the ECR-ITT population of 78.2% for solithromycin and 77.9% for moxifloxacin. The 95% confidence interval for the treatment difference had lower and upper bounds of -5.5% and 6.1%, respectively. Notably, solithromycin ECR rates were numerically higher than moxifloxacin in patients over 75 years of age with a treatment success rate of 83.9% for solithromycin and 69.8% for moxifloxacin. The 95% confidence interval for the treatment success rate in this age group had lower and upper bounds of -2.1 and 30.2, respectively. In addition, oral solithromycin demonstrated NI for the SFU-ITT endpoint with a success rate of 84.5% for solithromycin and 86.6% for moxifloxacin with a 95% confidence interval for the treatment difference at lower and upper bounds of -7.1 and 2.8, respectively. Treatment emergent adverse events were comparable for the two patient groups with 155 (36.6%) reported for solithromycin and 154 (35.6%) for moxifloxacin. There were no serious adverse events attributed to solithromycin. There were more Grade 4 ALT elevations among patients who received moxifloxacin (1.2%) compared to solithromycin (0.5%). In addition, there were two cases of C. difficile infection, both of which occurred in the moxifloxacin group.

Cempra, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cempra, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $17.4 million, or $0.41 per basic and diluted share, compared to a net loss of $17.0 million, or $0.51 per basic and diluted share, for the same period in 2014. Revenues were $13,963,000 compared to $3,083,000 a year ago. Loss from operations was $16,804,000 compared to $16,490,000 for the same period last year.

Cempra, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Cempra, Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 30, 2015

Cempra, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Cempra, Inc., Q1 2015 Earnings Call, Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $37.33 USD +0.59

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies
 

Industry Analysis

CEMP

Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.1x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.